TuHURA Biosciences, Inc.

As of June 30, 2026, TuHURA Biosciences, Inc. carries a market capitalization of 131.19M, placing it among publicly traded companies globally. Its enterprise value stands at 138.59M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

TuHURA Biosciences, Inc.'s next confirmed earnings release is scheduled for November 13, 2026.

As of June 30, 2026, TuHURA Biosciences, Inc. has 63.68M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, TuHURA Biosciences, Inc. maintains a current ratio of 0.18, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 49.62, indicating elevated leverage, while an interest coverage ratio of -27.75 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, TuHURA Biosciences, Inc. posted a negative return on equity (ROE) of -163.84, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -92.29, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 21.25, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, TuHURA Biosciences, Inc.'s stock has declined approximately 10.55% over the past 52 weeks. The 50-day moving average sits at 1.79, while the 200-day moving average is 1.69.

Over the twelve months ended June 30, 2026, TuHURA Biosciences, Inc. generated - - in revenue and converted that into -26.80M in net income, yielding earnings per share of -0.47. EBITDA reached -27.22M, while operating income came in at -23.86M.

As of June 30, 2026, TuHURA Biosciences, Inc. holds 871,778.67 in cash and equivalents against 8.03M in total debt, resulting in a net debt position of 6.81M. Total book value stands at 15.95M, with working capital of -6.65M providing operational flexibility.

TuHURA Biosciences, Inc. produced -25.99M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -187,028.85 in capital expenditures, free cash flow totaled -26.17M - equivalent to -0.46 per share.

Over the twelve months ended June 30, 2026, TuHURA Biosciences, Inc. paid dividends of 0.00 per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -22.15: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -14.94, meaning TuHURA Biosciences, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

TuHURA Biosciences, Inc.'s most recent stock split took place on October 18, 2024 with a 35:1 split ratio.

As of June 30, 2026, TuHURA Biosciences, Inc. has an Altman Z-Score of -26.11, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.